Linear Diagnostics Limited (LDL) has appointed Paul Thompson of Capel Thompson and Homer to seek potential partners to co-develop and market their Point of Care test for Chlamydia and Gonorrhoea which utilises the company’s proprietary Linear Dichroism technology.
Tim Dafforn, Professor of Biotechnology at the School of Biosciences at the University of Birmingham and a co-founder of LDL says: “This new duplex test will deliver accurate results in under 20 minutes, thus enabling the patient to be tested and treated in a single visit.”
Brendan Farrell, Chairman and CEO of Linear Diagnostics comments: “The speed, accuracy and convenience of the LDL duplex Chlamydia and Gonorrhoea test will help to slow the spread of sexually transmitted infections (STI’s) through the initiation of appropriate treatment at the test site. With WHO reporting that there are more than one million new STI’s worldwide every day, there is a very significant market opportunity for our lead product.”
To speak with Brendan Farrell or Professor Tim Dafforn, please contact ChrisLewis@clareville.co.uk
About Linear Diagnostics
Founded in 2011 and currently headquartered in the BioHub Birmingham® at the University of Birmingham Enterprise’s Birmingham Research Park, Linear Diagnostics Limited exploits the phenomenon of linear dichroism to detect various infectious diseases at the Point of Care.
The technology enables rapid detection of multiple targets using a disposable cartridge run on a small low-cost instrument. The platform technology has the potential to perform rapid, accurate and cost-effective diagnostic testing without the need for laboratory facilities.
